These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31037433)

  • 21. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.
    Zhao Z; Zhang Y; Wang X; Geng X; Zhu L; Li M
    Cancer Med; 2020 Aug; 9(16):5881-5888. PubMed ID: 32627960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?
    Chiu CH; Chao YK; Chang HK; Tseng CK; Chan SC; Liu YH; Chen WH
    Ann Surg Oncol; 2013 Dec; 20(13):4245-51. PubMed ID: 23959050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer.
    Xu X; Sun Z; Liu Q; Zhang Y; Shen L; Zhang C; Lin H; Hu B; Rong L; Chen H; Wang X; Zhao X; Bai YR; Ye Q; Ma X
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of effective dose to immune cells and vertebral marrow dose with hematologic toxicity during neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.
    Zhang M; Li Z; Yin Y
    BMC Cancer; 2024 Jun; 24(1):779. PubMed ID: 38943075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
    Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
    J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience.
    Nobel TB; Barbetta A; Hsu M; Tan KS; Pinchinat T; Schlottmann F; Bains MS; Ku GY; Wu AJ; Patti MG; Jones DR; Molena D
    J Gastrointest Surg; 2019 Jan; 23(1):11-22. PubMed ID: 30215197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
    Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
    Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone.
    Chen Y; Lu Y; Wang Y; Yang H; Xia Y; Chen M; Song H; Li T; Li D; Wang J; Li S; Wang J
    Dis Esophagus; 2014; 27(2):134-40. PubMed ID: 23088212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
    Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
    Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.
    Murakami M; Kuroda Y; Okamoto Y; Kono K; Yoden E; Kusumi F; Hajiro K; Matsusue S; Takeda H
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1049-59. PubMed ID: 9539559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
    Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
    Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
    Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010.
    Liu S; Wen J; Yang H; Li Q; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Zhao L; Liu H; Hu Y; Liu M; Fu J; Xi M
    Eur J Cancer; 2020 Oct; 138():113-121. PubMed ID: 32877795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy.
    Okumura H; Uchikado Y; Matsumoto M; Owaki T; Kita Y; Omoto I; Sasaki K; Sakurai T; Setoyama T; Nabeki B; Matsushita D; Ishigami S; Hiraki Y; Nakajo M; Natsugoe S
    Int J Clin Oncol; 2013 Apr; 18(2):329-34. PubMed ID: 22350023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.
    Motoori M; Yano M; Ishihara R; Yamamoto S; Kawaguchi Y; Tanaka K; Kishi K; Miyashiro I; Fujiwara Y; Shingai T; Noura S; Ohue M; Ohigashi H; Nakamura S; Ishikawa O
    Ann Surg Oncol; 2012 Jul; 19(7):2135-41. PubMed ID: 22302264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.
    Huang RW; Chao YK; Wen YW; Chang HK; Tseng CK; Chan SC; Liu YH
    World J Surg Oncol; 2014 May; 12():170. PubMed ID: 24885430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer.
    Kaneko K; Yano T; Minashi K; Kojima T; Ito M; Satake H; Yajima Y; Yoda Y; Ikematsu H; Oono Y; Hayashi R; Onozawa M; Ohtsu A
    Oncology; 2013; 84(1):57-64. PubMed ID: 23128894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy.
    Fujita K; Motoyama S; Sato Y; Wakita A; Nagaki Y; Minamiya Y; Miura M
    Med Oncol; 2021 Jan; 38(1):6. PubMed ID: 33411033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Sakai M; Sohda M; Miyazaki T; Honjo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Kuwano H
    Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.